NY-IWBI
8.6.2020 17:03:03 CEST | Business Wire | Press release
The International WELL Building Institute (IWBI) announced today the launch of the WELL Health-Safety Rating for all building and facility types, an evidence-based, third-party verified rating focusing on operational policies, maintenance protocols and design strategies to address a post COVID-19 environment. The WELL Health-Safety Rating is one of the earliest outcomes of IWBI’s Task Force on COVID-19 , a group of nearly 600 public health experts, virologists, government officials, academics, business leaders, architects, designers, building scientists and real estate professionals, which was established in late March to help guide IWBI’s response to the pandemic.
The WELL Health-Safety Rating provides a centralized source and governing body to validate efforts made by owners and operators. It leverages insights drawn from the IWBI COVID-19 Task Force, in addition to guidance on the spread of COVID-19 and other respiratory infections developed by the Centers for Disease Control and Prevention (CDC), the World Health Organization (WHO), the Department of Health and Human Services pursuant to the Occupational Safety and Health Act (OSHA), the National Institutes of Health (NIH), and leading academic and research institutions, as well as core principles already established by IWBI’s WELL Building Standard. Participation in the program requires submission of policies, protocols and strategies for third-party document review and annual verification.
“The WELL Health-Safety Rating is a sign of confidence that measures have been enacted to help support the health and safety of people entering spaces of all kinds, and that those measures have been mapped to scientific evidence and verified through a third-party review process,” said Rick Fedrizzi, chairman & CEO of IWBI. “By drawing on the proven strategies in WELL, we’re working from the best science available and that’s more important than it’s ever been.”
The WELL Health-Safety Rating will accept registrations in June from all types of buildings and facility typologies, including offices, restaurants, hotels, retail establishments, manufacturing plants, warehouses, sports stadiums, arenas, theaters and other entertainment venues, schools, multi-family housing, and many others. Current WELL-registered projects and WELL Portfolio participants can earn the WELL Health-Safety Rating as part of their already established certification efforts.
“Our buildings and the people who tend them are our first line of defense for keeping us safe and healthy,” said Rachel Gutter, president of IWBI, “and the current pandemic has confirmed that health is a material economic consideration of the first order. These two simple truths stand at the nexus of our work to date and will, along with the hard evidence that is mounting, inform all our decisions about the critical need for better buildings, more vibrant communities and stronger organizations going forward.”
The WELL Health-Safety Rating is the first of many anticipated outcomes informed by the work of the IWBI COVID-19 Task Force that will be introduced in the coming months. Members of the Task Force include 17th Surgeon General of the United States Dr. Richard Carmona, former Robert Wood Johnson Foundation President and CEO Dr. Risa Lavizzo-Mourey, UCLA’s Dr. Jonathan Fielding, Harvard School of Public Health’s Joseph Allen, and environmental scientist Allen Hershkowitz Ph.D., among others.
“The Task Force has received overwhelming support and input from all over the world,” said Dr. Richard Carmona, 17th Surgeon General of the United States. “People are learning that buildings themselves can be powerful vehicles for protecting and improving public health. All of us individually have a responsibility to the collective whole to use every tool, including our buildings and our sense of community, to keep ourselves and those we care about safe.”
“The impacts of the virus have been many, but not the least is the anxiety of uncertainty about where people feel safe,” said Despina Katsikakis, Head of Occupier Business Performance at Cushman Wakefield and member of IWBI’s COVID-19 Task Force. “Achieving this new WELL Health-Safety Rating is a great way to increase confidence that evidence-based steps to do the right thing have been taken to keep health front and center as the economy reopens.”
Recently, IWBI released an interim Strategies from the WELL Building Standard to Support in the Fight Against COVID-19, another key outcome of the Task Force. Grounded in the foundation of WELL, these evidence-based strategies provide an actionable framework for organizations and communities as they advance a safer and healthier future. IWBI is expanding these strategies into Guidelines for Preparedness and Prevention, Resilience and Recovery in relation to COVID-19 and other respiratory infections. The Guidelines will provide insight into how the current strategies have evolved, as well as indicate areas where further work is required.
Since its inception, IWBI has been driving forward the convergence of building science and health science. Registrations under the WELL Building Standard, the premier standard for healthy real estate, have already surpassed 550 million square feet across 62 countries. The WELL Building movement has been further amplified by over 11,000 WELL Accredited Professionals (APs) and registrants across the globe.
Gutter noted that upon achieving the designation, IWBI will issue the project a WELL Health-Safety Rating seal. Register interest in the WELL Health-Safety Rating here .
About the International WELL Building Institute
The International WELL Building Institute (IWBI) is leading the global movement to transform our buildings, communities and organizations in ways that help people thrive. The WELL v2 pilot is the latest version of its popular WELL Building Standard (WELL), and the WELL Community Standard pilot is a district scale rating system that sets a new global benchmark for healthy communities. WELL is focused exclusively on the ways that buildings and communities, and everything in them, can improve our comfort, drive better choices, and generally enhance, not compromise, our health and wellness. IWBI mobilizes the wellness community through management of the WELL AP credential, the pursuit of applicable research, the development of educational resources, and advocacy for policies that promote health and wellness for everyone, everywhere. For more information about IWBI and WELL, visit us here .
International WELL Building Institute, IWBI, the WELL Building Standard, WELL v2, WELL Certified, WELL AP, WELL, WELL Portfolio, The WELL Conference, the WELL Community Standard, WELL Workforce, WELL Health-Safety Rating and others, and their related logos are trademarks or certification marks of International WELL Building Institute pbc in the United States and other countries.
View source version on businesswire.com: https://www.businesswire.com/news/home/20200608005495/en/
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 19:42:00 CEST | Press release
- Vertex is on track for the U.S. FDA Prescription Drug User Fee Act (PDUFA) date of November 30 for potential accelerated approval of povetacicept –- Data published in NEJM and presented at ASN highlight povetacicept’s unique trifecta of efficacy, favorable safety, and the simplicity of dosing at-home every 4 weeks with a low-volume autoinjector –- Data presented at ASN include a qualitative study examining patient perspectives on current and emerging IgAN therapies, showing that 96% of participants preferred an autoinjector over a prefilled syringe, and 80% of participants preferred dosing every 4 weeks versus weekly dosing - - New clinical studies of povetacicept underway including a study evaluating patient experience on povetacicept administered via autoinjector - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Soc
BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 16:15:00 CEST | Press release
New data from HERIZON-GEA-01 Phase 3 trial show 36-month overall survival of nearly 40% with TEVIMBRA plus ZIIHERA and chemotherapy, and median OS reaching 27 monthsTEVIMBRA-containing arm was associated with a four-month longer median OS compared with ZIIHERA plus chemotherapy BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne,
Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 16:10:00 CEST | Press release
Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com
inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 15:00:00 CEST | Press release
Collaboration will establish the roadmap for bringing Pony.ai robotaxis to Kazakhstan on the inDrive ride-hailing platform, leveraging the NVIDIA Hyperion and the NVIDIA Halos safety system. inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a lea
Brenus Pharma's Novel In Vivo Immunotherapy STC-1010 Shows Safety, Activating T Cells in First-Line MSS Metastatic Colorectal Cancers With 2 Complete Responses.23.10.2026 14:50:00 CEST | Press release
Phase Ia BreAK CRC-001 at ESMO 2026: 43% of patients, all initially unresectable, became eligible for surgery Poster 1023P – Developmental Therapeutics Brenus Pharma, a clinical-stage biotech company, announced first data from the Phase Ia dose escalation of BreAK CRC-001. Nine unresectable patients were treated; 89% had liver metastases and 89% KRAS-mutant tumors, a population refractory to immunotherapy. Median follow-up: 8 months (1–14; data cut-off 6/08/2026). 95% of metastatic colorectal cancers are pMMR/MSS tumors, poorly immunogenic and resistant to immunotherapy. STC-1010, the company’s lead in vivo DC-engager, is designed to make these “cold” tumors visible to immune cells. Safety: no dose-limiting toxicity, only grade 1–2 related adverse events. Clinical activity (seven evaluable patients, RECIST 1.1): 100% disease control, 57% objective response rate (4/7). 43% of patients became operable (3/7): two with no evidence of disease afterward. Molecular profile: ctDNA dropped by u
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
